BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Safety and Efficacy of Medical Cannabis in Fibromyalgia.
Authors: Iftach Sagy, Lihi Bar-Lev Schleider, Mahmoud Abu-Shakra, Victor Novack
Journal of Clinical Medicine, 5 June 2019
—
BACKGROUND: Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and effectiveness of medical cannabis thera…
Should Oncologists Recommend Cannabis?
Authors: Donald I. Abrams
Current Treatment Options in Oncology, 3 June 2019
—
Cannabis is a useful botanical with a wide range of therapeutic potential. Global prohibition over the past century has impeded the ability to study the plant as medicine. However, delta-9-tetrahydrocannabinol (THC) has been developed as a stand-alone pharmaceutical initially …
Cannabidiol Adverse Effects and Toxicity.
Authors: Marilyn A. Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, et al
Current Neuropharmacology, 3 June 2019
—
BACKGROUND: Currently, there is great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. M…
Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.
Authors: Stephanie McGrath, Lisa R. Bartner, Sangeeta Rao, Rebecca A. Packer, Daniel L. Gustafson
Journal of the American Veterinary Medical Association, 1 June 2019
—
OBJECTIVE: To assess the effect of oral cannabidiol (CBD) administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with idiopathic epilepsy. DESIGN: Randomized blinded controlled clinical trial. ANIMALS: 26 client-owned dogs with intracta…
Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.
Authors: Thangam Venkatesan, David J. Levinthal, B U. K. Li, Sally E. Tarbell, Kathleen A. Adams, et al
Neurogastroenterology and Motility, June 2019
—
Cannabis is commonly used in cyclic vomiting syndrome (CVS) due to its antiemetic and anxiolytic properties. Paradoxically, chronic cannabis use in the context of cyclic vomiting has led to the recognition of a putative new disorder called cannabinoid hyperemesis syndrome (CHS…
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
Authors: Elizabeth Steels, Ruchitha Venkatesh, Eleanor Steels, Gemma Vitetta, Luis Vitetta
Inflammopharmacology, June 2019
—
BACKGROUND: The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis. METHODS: This was a single site, comparative, double-blind placebo controlled study i…
Humboldt Humbled by Legalization
Although it’s entitled “How Legalization Changed Humboldt County Marijuana,” Emily Witt’s article in the New Yorker is not about new plant varieties but about new social realities.
Cannabis: From a Plant That Modulates Feeding Behaviors toward Developing Selective Inhibitors of the Peripheral Endocannabinoid System for the Treatment of Obesity and Metabolic Syndrome.
Authors: Shira Hirsch, Joseph Tam
Toxins, 15 May 2019
—
In this review, we discuss the role of the endocannabinoid (eCB) system in regulating energy and metabolic homeostasis. Endocannabinoids, via activating the cannabinoid type-1 receptor (CB1R), are commonly known as mediators of the thrifty phenotype hypothesis due to their act…
Anti-tumour actions of cannabinoids.
Authors: Burkhard Hinz, Robert Ramer
British Journal of Pharmacology, May 2019
—
The endocannabinoid system has emerged as an important target for the treatment of many diverse diseases. In addition to the well-established palliative effects of cannabinoids in cancer therapy, phytocannabinoids, synthetic cannabinoid compounds and inhibitors of endocannabin…
Species-specific susceptibility to cannabis-induced convulsions.
Authors: Benjamin J. Whalley, Hong Lin, Lynne Bell, Thomas Hill, Amesha Patel, Roy A. Gray, C. Elizabeth Roberts, Orrin Devinsky, Michael Bazelot, Claire M. Williams, Gary J. Stephens Published in…
Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications.
Authors: Arulkumar Nagappan, Jooyeon Shin, Myeong Ho Jung
International Journal of Molecular Sciences, 29 April 2019
—
Endogenous cannabinoids (ECs) are lipid-signaling molecules that specifically bind to cannabinoid receptor types 1 and 2 (CB1R and CB2R) and are highly expressed in central and many peripheral tissues under pathological conditions. Activation of hepatic CB1R is associated with…
Cannabinoid hyperemesis syndrome: An unrecognized cause of nausea and vomiting.
Authors: Tiffany N. Smith, Anne Walsh, Christopher P. Forest
Journal of the American Academy of Physician Assistants, April 2019
—
Cannabis has long been used for medical and recreational purposes because of its antiemetic, analgesic, and mood effects. Ironically, chronic use of cannabis can result in paradoxical effects, including a condition known as cannabinoid hyperemesis syndrome. Patients with this …